A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2028

Conditions

Acute Graft-versus-Host Disease

Interventions

BIOLOGICAL

iMSC

1× 10\^6/kg each time, twice a week

COMBINATION_PRODUCT

conventional aGVHD prophylaxis

Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）

All Listed Sponsors

lead

Ruijin Hospital

OTHER